Diabetes Treatment

The company emphasised that it is ready to meet the growing demand for drug-device combinations and biologics, with semaglutide formulations being a focal point

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children

In 2022, there were around 828 million people aged 18 years and older with type 1 and type 2 diabetes worldwide, the study found

Adipose tissue cells from the patient were reprogrammed into stem cells, converted to islet cells, and transplanted back, eliminating the risk of immune rejection as they were from her own body

Also known as latent autoimmune diabetes in adults (LADA), type 1.5 diabetes has features of both type 1 and type 2 diabetes

A 59-year-old man with type 2 diabetes received an innovative cell transplant and has been insulin-free and off medication for 33 months, offering hope to other diabetes patients

The sales of Novo Nordisk's Rybelsus tablet, used for diabetes treatment and weight reduction, more than doubled to Rs 363 crore this year from Rs 147 crore last year

Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement. It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed. Lirafit will be available only under prescription. "Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said. Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added. "W

The findings, published in JAMA Network Open, showed that men were more likely to develop diabetes than women

Glenmark Pharmaceuticals on Monday said it has launched a novel fixed-dose combination (FDC) of Teneligliptin, with Pioglitazone in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement. Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients, Glenmark Pharmaceuticals Group Vice President & Head, India Formulations Alok Malik said. Glenmark claimed it is the "first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India)" "This fixed-dose combination will be

Glenmark said it has become the first company in the world to launch the fixed dose combination drug in India

Ahead of World Diabetes Day, a new report has called for action to close the gap in diabetes prevention and care

Unhealthy food habits lead to weight gain and obesity, insulin resistance which in turn causes both diabetes and predisposes to infertility

The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children

A chemical in broccoli tamped down glucose production by liver cells in rats

In Primates treatment has shown to last for weeks, rather than days, says researchers